Last edition
News about "atopic dermatitis "
Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.
Atopic Dermatitis | 16/12/2025 | By News Bureau | 131
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
Atopic Dermatitis | 14/10/2025 | By Dineshwori | 248
Amgen and Kyowa Kirin Report Phase-III Results for Rocatinlimab in Atopic Dermatitis
Amgen and Kyowa Kirin report top-line results from ongoing ASCEND study evaluating Rocatinlimab’s long-term safety and efficacy in adults with moderate to severe Atopic Dermatitis following prior ROCKET trials.
Atopic Dermatitis | 09/09/2025 | By Dineshwori | 169
Sanofi's Amlitelimab Achieves Key Milestone in Phase-III Trial for Atopic Dermatitis
Sanofi’s amlitelimab demonstrates sustained efficacy and improved disease outcomes, highlighting the potential to reshape the treatment for atopic dermatitis.
Atopic Dermatitis | 04/09/2025 | By Dineshwori | 287
Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.
Atopic Dermatitis | 17/09/2024 | By Aishwarya | 669
Johnson & Johnson to Acquire Proteologix to Expand its Portfolio
Johnson & Johnson has signed a definitive agreement to acquire Proteologix, Inc. for USD 850 million in cash, with the potential for an additional milestone payment.
Atopic Dermatitis | 17/05/2024 | By Aishwarya | 625
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy